Download now: Cannabis Cash

Investing in the End of Pandemics

Written by Jeff Siegel
Posted May 13, 2021

*Editor’s Note: Our Catalyst Calendar event is available to view right now. Watch the recording of the event here.

There was an interesting piece in Reason magazine recently titled, "Why COVID-19 May Be the Last Pandemic.”

The argument is that medical breakthroughs in the world of biotech — such as “messenger RNA” vaccines — will result in the global community never having to suffer from diseases like COVID-19 again.

Reason science correspondent Ronald Bailey writes:

The horrors of the last year have spurred humanity to quickly develop an unprecedentedly flexible and powerful tool kit that may well make COVID-19 the last true pandemic.

Now you can just slip any piece of genetic information into [a] lipid and... you have a vaccine.

While I know vaccine debates make for great political fodder, the bottom line is that most of us are alive today because of vaccines. And in the case of messenger RNA vaccines, this is just the next evolution of vaccine science — and an amazing opportunity for investors to make a lot of money.

A 1,438% Gain in Less Than Two Years

One of the biggest winners in the race for a COVID-19 vaccination was BioNTech (NASDAQ: BNTX).

BioNTech is a German player that was specializing in messenger RNA before the pandemic hit us with all the subtlety of a brick to the face.

It was actually one of the biggest biotech listings of all time when it went public, with a valuation of $3.4 billion.

Still, despite the enthusiasm over the stock, you could’ve bought shares of this thing for as little as $16 a share. Pretty cheap considering the company was a leader in this new messenger RNA technology.

And of course, after the company inked a deal with Pfizer and began developing a vaccine for COVID-19, the stock skyrocketed to more than $200 a share.


That’s a 1,438% gain in less than two years.

That, my friend, is how biotech billionaires are created.

Of course, not every biotech play is going to pay off like BNTX.

Truth is, most investors just don’t have access to the kind of intel that can tip you off to a $13 stock that’ll soon be worth $200.

Just like anything, it’s all about access.

Like George Carlin said, “It’s a big club, and you ain’t in it.”

But you don’t have to be in the club to get access to this kind of intel.

You just need access to someone who does.

And next week, we’re going to introduce you to that person.

Moreover, we’re going to show you how to use his access to the world of biotech billionaires so you can get some of this action for yourself in a special webinar you’ll be able to attend absolutely free.

Just click here now to lock in your spot as spaces are limited.

I’ll certainly be there, and I look forward to seeing you there too.

To a new way of life and a new generation of wealth...

Jeff Siegel Signature

Jeff Siegel

follow basic@JeffSiegel on Twitter

Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's page.

Hydrogen Fuel Cells: The Downfall of Tesla?